COVAXIN Price is now Rs. 225/- per dose at Private Hospitals. We welcome the decision to make available precautionary dose for all adults. In consultation with the Central Government, we have decided to revise the price of #COVAXIN from Rs 1200 to Rs 225 per dose, for private hospitals, Suchitra Ella the Joint Managing Director of Bharat Biotech Tweeted.
Check out the New Covaxin Price and More
- Private hospitals are requested to provide COVAXIN at the revised rate effective 10th April 2022. The price differential with any existing stocks of COVAXIN in private hospitals shall be compensated in the form of additional doses.
- Fresh stocks of COVAXIN are available and ready for supplies. Bharat Biotech has more than 50 million doses of COVAXIN readily available in vials, and over 200 million doses as drug substance. Additional production capacity is also available to meet product demand.
COVAXIN® is formulated uniquely such that the same dosage can be administered to adults and children alike. COVAXIN® is a ready-to-use a liquid vaccine, stored at 2-8°C, with 12 months shelf life and multi-dose vial policy. The same vaccine can also be used for 2 dose primary immunization and for booster dose vaccinations, making it truly an universal vaccine.
Covaxin : New study reveals’ elevated responses
Meanwhile a new study established a booster dose of Covaxin administered six months after the two dose primary vaccination has shown elevated immune responses against SARS-CoV-2 variants of concern including Omicron and protection from severe disease, a study by ICMR and Bharat Biotech has found.
The emergence of Omicron with at least 30 mutations within most vaccines’ target region – the spike protein – raised an alarm about its immune escape from vaccine-induced neutralising antibodies, thereby leading to increased transmissibility and causing breakthrough and reinfection, senior scientist at the National Institute of Virology (NIV) in Pune, Dr Pragya Yadav, told news agency PTI.
Additionally, reports of waning of antibody responses against the emerging variants of concern (VoCs) of virus for other approved vaccines have raised concern globally, she said.
As a part of the study the antibody responses in sera of 51 participants who received two doses of Covaxin collected six months post second dose and 28 days after receiving a third (booster) dose (given on day 215th post second dose) and its impact against the Omicron VoC was evaluated.
The study by the Indian Council of Medical Research (ICMR) and Covaxin manufacturer Bharat Biotech was conducted in January and the findings were published in the Journal of Travel Medicine on March 24.
“The antibody response was higher for participants administered with booster doses for B.1 and the VoCs – Delta, Beta and Omicron variants,” Dr Gajanan Sakpal, another senior scientist at the NIV, said.
This indicates that the booster dose of Covaxin robustly triggered neutralising antibody responses and efficiently neutralised the multiple variants of SARS-CoV-2, Mr Sakpal said.
